Travere Therapeutics (TVTX) has transformed into a commercial-stage rare disease company with accelerating revenue from FILSPARI (sparsentan) in IgA nephropathy (IgAN), recent full FDA approval for focal segmental glomerulosclerosis (FSGS), narrowing losses, and a Strong Buy analyst consensus with rising price targets, though facing increasing competition in IgAN and execution risks on pipeline assets.
Fact: Travere Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and commercializing therapies for rare kidney and metabolic diseases. It has approximately 497 full-time employees and was formerly known as Retrophin, Inc. (name changed November 2020). CEO is Eric M. Dube, Ph.D. Yahoo Finance Profile | Company Website
Data Limitation: Historical details primarily from company disclosures and secondary sources; exact early acquisition timelines may vary by report.
IR Website for History/Press ReleasesFact: Over the past 5 years, TVTX has delivered substantial total returns significantly outperforming the S&P 500, driven by clinical and regulatory successes with FILSPARI. 1-year returns have also been strong (approximately 230-260% in recent periods).
| Period | TVTX Approximate Total Return | S&P 500 Approximate Total Return |
|---|---|---|
| 1-Year | +230% to +262% | +18% |
| 3-Year | +225% | +63% |
| 5-Year | +292% to +306% | +70% |
Data Limitation/Assumption: Returns are approximate based on available historical data as of early August 2026 reports; exact figures depend on specific start/end dates and exclude dividends (none paid). Past performance is not indicative of future results. Yahoo Finance Historical Data | Macrotrends Stock History
Fact: Revenue has grown rapidly primarily from U.S. net product sales of FILSPARI. Full year 2025: U.S. FILSPARI sales ~$322M (total net product sales ~$410M); trailing periods show continued growth into 2026 quarters. Net losses have narrowed significantly (e.g., full year 2025 net loss ~$25.5M vs. $321.5M prior year); some quarters turned profitable on GAAP or non-GAAP basis. Cash, cash equivalents, and marketable securities: ~$265M-$490M range across recent reports (including milestones).
| Metric (Approximate, Recent Periods) | Full Year 2025 | Q1 2026 Example | TTM/Recent Notes |
|---|---|---|---|
| Total Revenue / Net Product Sales | ~$410M (FILSPARI dominant) | ~$124.5M FILSPARI | Growing; Q2 2026 updates show continued demand (e.g., new patient starts) |
| Net Income (Loss) | -$25.5M | -$37.1M | Narrowing; non-GAAP often positive |
| Cash Position | ~$323M (end 2025) | ~$265M (end Q1) | Supported by operations and milestones (e.g., $25M from Mirum) |
Interpretation: Strong commercial execution on FILSPARI is driving top-line growth and improving profitability trajectory, positioning the company for potential sustained positive cash flow if FSGS launch succeeds.
Uncertainty: Future revenue depends on FSGS uptake, IgAN competition intensity, and pipeline outcomes (e.g., pegtibatinase HARMONY study topline in 2H 2026).
Data Limitation: Financial figures from company press releases and filings (e.g., 10-Q/earnings reports through Q2 2026); exact quarterly breakdowns and 2026 guidance may be limited or updated. No forward-looking projections included here. IR Quarterly Results | Yahoo Financials
Fact: Consensus rating is Strong Buy (11 Buy, 1 Hold from ~12-15 analysts). Average 12-month price target approximately $59 (range $43 low to $70 high), with multiple upward revisions in 2026 tied to FILSPARI progress, FSGS approval, and pipeline deals (e.g., civorebrutinib licensing).
| Recent Analyst Actions (2026 Examples) | Firm | Rating | Price Target Change |
|---|---|---|---|
| July 2026 | Canaccord Genuity | Buy (Maintained) | Raised to $62 (from $56) |
| July 2026 | BofA Securities | Buy | Raised to $64 (from $59) |
| June 2026 | Guggenheim | Buy | Raised to $65 (from $56) |
| June 2026 | Citi | Buy | Raised to $70 (from $62) |
| June 2026 | Wedbush | Outperform | Raised to $61 (from $55) |
Interpretation: Upward target revisions reflect optimism around commercial momentum and first-mover advantage in FSGS, though valuation concerns and competition are noted in some commentary.
Uncertainty: Ratings and targets can change rapidly with new clinical data, earnings, or macro events; one Hold rating exists amid high valuation discussions.
Data Limitation: Consensus as of latest available reports (July/August 2026); individual analyst views may differ. TipRanks Forecast | Yahoo Analyst Insights
Interpretation: The model relies on specialized healthcare providers and patient communities rather than broad retail; partnerships extend global reach and de-risk development.
Pipeline & Partners Page | Patient AdvocacyFact: In IgAN: Novartis (Fabhalta/iptacopan complement inhibitor; Vanrafia/atrasentan), Otsuka (Voyxact/APRIL inhibitor), Vera Therapeutics (atacicept in review), Vertex (povetacicept advancing). In FSGS: Travere holds first-and-only approved therapy status with limited near-term competition (potential future from BioMarin, Boehringer Ingelheim mentioned in reports).
| Indication | Key Competitors / Therapies | Status / Notes |
|---|---|---|
| IgAN | Novartis (Fabhalta, Vanrafia); Otsuka (Voyxact); Vera (atacicept); Vertex (povetacicept) | Multiple approved or late-stage; increasing mechanistic diversity (complement, APRIL/BAFF, etc.) |
| FSGS | Travere (FILSPARI first approved); others in earlier development | Limited near-term competition; 3+ year headstart noted by analysts |
| Other (Cystinuria, HCU) | Generic or limited options; emerging enzyme therapies | Thiola established; pegtibatinase in Phase 3 |
Interpretation: FILSPARI's dual endothelin/angiotensin mechanism and non-immunosuppressive profile provide differentiation, but IgAN competition could pressure market share; FSGS position is stronger.
Uncertainty: Competitive landscape evolving rapidly with new approvals and trial readouts; exact market share impact uncertain without long-term data.
Data Limitation: Competitor status based on public reports as of mid-2026; pipeline statuses subject to change. Seeking Alpha Analysis | BioSpace News
Overall Data Limitations and Assumptions: All information synthesized from publicly available web sources as of early August 2026. Financials and stock data are historical/reported (not real-time); analyst views are consensus snapshots. No investment advice is provided. Verify with latest SEC filings (10-Q/10-K), company IR, and professional advisors. Market conditions, regulatory decisions, and clinical results introduce inherent uncertainties.